Odunsi Kunle, Lele Shashikant, Savalgi Raghu
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
Surg Technol Int. 2004;13:39-47.
Great strides in the understanding of regulation of the immune system have led to development of strategies to harness the potential of cellular immune responses for improving the outcome for cancer patients. To generate a cytotoxic T-lymphocyte (CTL) response to cancer cells requires tumor-specific antigens processed appropriately and displayed by major histocompatibility complex (MHC) molecules, T-lymphocytes with receptors of appropriate specificity, and co-stimulation delivered by antigen-presenting cells through members of the B7 family. In this review, the fundamental advances that have been made in tumor antigen discovery, and the novel vaccine approaches arising from these advances are discussed.
在理解免疫系统调节方面取得的巨大进展，促使人们开发出利用细胞免疫反应潜力来改善癌症患者治疗结果的策略。要产生针对癌细胞的细胞毒性T淋巴细胞（CTL）反应，需要主要组织相容性复合体（MHC）分子适当加工并呈递肿瘤特异性抗原，具有适当特异性受体的T淋巴细胞，以及抗原呈递细胞通过B7家族成员传递的共刺激信号。在这篇综述中，将讨论肿瘤抗原发现方面取得的基本进展，以及基于这些进展产生的新型疫苗方法。
